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a b s t r a c t
Objectives: To assess risk prediction in patients with acute coronary syndrome (ACS) during
the hospital stay, at 6 weeks and at 6 months period using high sensitivity C-reactive protein
(hs-CRP), serum creatinine, cardiac troponin I, creatine kinase total, and MB levels.
Methods: It was a prospective observational study. The primary outcome was taken as all-
cause mortality. Patients with ACS were enrolled and followed up at 6 weeks and 6 months
duration from the index event. Mortality and cause of death were recorded. The hs-CRP was
estimated on admission, at 6 weeks, and at 6 months. The estimated glomerular ﬁltration
rate (eGFR) was calculated using the abbreviated modiﬁcation of diet in renal disease (MDRD)
formula at admission, at 6 weeks, and 6 months.
Results: There were a total of 108 cases of ACS in the duration of 6 months who completed
the follow-up. The hs-CRP level of >5 mg/dl was highly signiﬁcant for predicting mortality
during hospital stay and at 6 weeks ( p < 0.001). There was 11% of in-hospital mortality
( p < 0.001). At 6 months, the overall mortality was 28% ( p < 0.001). There was a statistical
signiﬁcance with low eGFR (median eGFR 45 ml/min/1.73 m2) levels during the admission.
Conclusion: hs-CRP levels above 5 mg/dl and the eGFR levels ≤30 ml/min/1.73 m2were signiﬁ-
cant in predicting mortality of the patients with ACS. This may provide simple assessment
tools for predicting outcome in ACS in resource-poor settings if validated further.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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Cardiovascular disease (CVD) is the prevailing non-communi-
cable cause of death and disability in the Indian subcontinent,* Corresponding author.
E-mail address: prahladkarki@hotmail.com (P. Karki).
http://dx.doi.org/10.1016/j.ihj.2015.06.029
0019-4832/# 2015 Cardiological Society of India. Published by Elsevierand will become the prevailing overall cause of mortality
among the inhabitants of South Asia in the next 20 years. The
current epidemic and imminent growth are due to the huge
burden of CVD risk factors, largely driven by urbanization.1,2
Although we do not have any national data on ischemic heart B.V. All rights reserved.
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increasing and there is a ﬁvefold increase in the incidence of
coronary artery disease (CAD).3
The signiﬁcance of the contribution of laboratory medi-
cine to clinical cardiology has grown in importance over the
years. This is witnessed by the recent incorporation of
biomarkers into new international guidelines and in the re-
deﬁnition of myocardial infarction (MI). There are mainly
two classes of indicators: markers of early injury/ischemia
and markers of inﬂammation and coronary plaque instabil-
ity and disruption.4
There are various biomarkers associated with acute
coronary syndrome (ACS). The clinical application of
cardiac biomarkers in ACS is no longer limited to establishing
or refuting the diagnosis of myocardial necrosis. Cardiac
biomarkers provide a convenient and noninvasive means to
gain insights into the underlying causes and consequences of
ACS that mediate the risk of recurrent events and may be
targets for speciﬁc treatment.4 Biochemical markers play a
major role for risk assessment in patients with an ongoing
non-ST segment elevation ACS. Although the cardiac troponin
in particular is generally recognized as an important risk
indicator, other markers of left ventricular performance (i.e. N-
terminal pro-brain natriuretic peptide), inﬂammation (i.e. C-
reactive protein), and renal function (i.e. estimated glomerular
ﬁltration rate (eGFR)] are equally important in providing strong
prognostic information.5,6
With the availability of highly speciﬁc and sensitive
methods for evaluating myocardial tissue damage, such as
the immunoassays for MB isoenzyme of creatine kinase (CK
MB), myoglobin, and especially, cardiac speciﬁc troponin T and
I (cTnT and cTnI) and their introduction in clinical practice, the
deﬁnition of acute myocardial infarction (AMI) has radically
changed.7
The information gathered from this study would help us in
various ways. Firstly, it will help us predict the outcomes of the
patients with ACS using the commonly used biomarkers and
thus the treatment of the patient can be guided. The
demographic information provided by this study shows us
that ACS is increasing in Nepal, especially in the young
population. This study provides us a complete proﬁle of
patients with ACS.
2. Objective
The study was undertaken to assess risk prediction in patients
with ACS during the hospital stay, at 6 weeks, and at 6 months
period using high sensitivity C-reactive protein (hs-CRP),
serum creatinine, cTnI, and CK MB fraction.
3. Materials and methods
3.1. Study design
The study was hospital-based prospective observational
study, which was more practical in our setting and ethically
acceptable.3.2. Setting
This study was conducted in the Department of Internal
Medicine at B.P. Koirala Institute of Health Sciences, Dharan,
Nepal for a period of 1 year.
3.3. Primary outcome
All-cause mortality.
3.4. Inclusion criteria
All the patients meeting the diagnostic criteria of ACS, who
were admitted under the Department of Internal Medicine at B.
P. Koirala Institute of Health Sciences and who gave consent,
were enrolled for this study.
3.5. Exclusion criteria
Alternate diagnosis of chest pain and/or refusal to give consent
for the study.
For the purpose of the study, different components of ACS were
deﬁned as following:
(1) ST elevation Myocardial Infarction (STEMI):
(a) Characteristic rise and fall of cardiac biomarkers
(presence of troponin I, and/or rise of CK NAC and CK
MB)
And
(b) Central ischemic chest pain (described as retro-
sternal pressure, pain, discomfort, or heaviness radiat-
ing to neck, jaw, left arm, or shoulder precipitated by
exertion more than 20 min)
And/or
(c) Typical ischemic ECG changes:
 ST elevation in at least two contiguous leads, ≥0.2 mV in
leads V1–V3 or ≥0.1 mV in all other leads.
 Established MI (in the absence of confounders) is
indicated by any Q wave in leads V1–V3 or by Q waves
of ≥1 mm for ≥30 ms in two other contiguous leads.
 Presumed new left bundle branch block.
(2) Non-ST elevation myocardial infarction (NSTMI): Features
as described for STEMI, but not meeting electrocar-
diographic ST-T criteria.
(3) Unstable angina:
At least one of the following:
(a) Chest discomfort occurring at rest or at minimal
exertion and lasting for >10 min;
(b) Is new onset and severe (within last 6 weeks);
(c) Occurs with crescendo pattern.
3.6. Variables studied
Cardiac troponin I (cTnI), hs-CRP, eGFR using four variable
modiﬁcation of diet in renal disease (MDRD) equation, and
serum CK MB levels in patients with ACS during index event, at
6 weeks, and 6 months.
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All the consecutive patients with the diagnosis of ACS and who
gave informed consent for the study were enrolled and
followed up at 6 weeks and 6 months duration from the index
event. Mortality and the likely cause of death were recorded
along with the day since admission. The hs-CRP was estimated
on admission, at 6 weeks, and at 6 months. The eGFR was
calculated using the abbreviated MDRD formula at admission,
at 6 weeks, and 6 months. For estimating cTnI, qualitative
membrane-based immunoassay was used. For estimating CK,
the serum sample was analyzed using a semi-automatic
analyzer using standard commercially available kits on
admission. The patient socioeconomic status was assessed
by modiﬁed family income groups in Nepalese Rupees of the
Kuppuswamy's socioeconomic status scale modiﬁed for 2009.8
3.8. Statistical analysis
The sample size was calculated as per the WHO's Software for
calculating sample size depending on the prevalence of ACS as
per the previous epidemiological study in the same setting.9
Data were entered in Microsoft Excel 2000 and converted
into SPSS version 10 for statistical analysis. Median was
calculated for the demographic presentation of the sample. InTable 1 – Socio-demographic characteristics of patients with ac
Characteristics Categories 
Age groups (in years) <55 
55–75 
>75 
Median age in years (IQR) 
Sex Male 
Female 
Education Illiterate 
Literate 
Formal education 
Kuppuswamy's scale Upper 
Middle 
Upper lower 
Lower 
Body mass index (kg/m2) <18.5 
18.5–23 
23–27.5 
>27.5 
Median body mass index in kg/m2 (IQR) 
Abdominal circumference (males) in cm <90 
≥90 
Median abdominal circumference of males in cm (IQR) 
Waist hip ratio males <0.9 
≥0.9 
Median waist hip ratio of males (IQR) 
Abdominal circumference (females) in cm <80 
≥80 
Median abdominal circumference of females in cm (IQR) 
Waist hip ratio female <0.8 
≥0.8 
Median waist hip ratio of females (IQR) the bivariate analysis for the numerical data in both the groups
(improved or death at 6 months), mean comparison was done
and p value was calculated using the non-parametric test
(Mann–Whitney U test). Percentage, graphical presentation,
and other descriptive statistics were calculated. Multiple
variables, which were signiﬁcantly affecting the outcome,
were together taken into multivariate logistic regression
analysis. The signiﬁcance level of the data, which were taken
for the multivariate analysis, was ≤0.05 at the bivariate
analysis.
3.9. Ethical clearance
Ethical clearance was taken as per the guidelines of Institu-
tional ethical review board (IERB), BPKIHS, Dharan.
4. Results
There were a total of 114 cases of ACS in duration of 6 months.
As 6 patients did not complete the follow-up, they were
excluded from the study. The total numbers included in the
ﬁnal analysis were 108, out of which 44 were STEMI, 41
were NSTEMI, and 23 were unstable angina (UA) (Fig. 1 and
Table 1).ute coronary syndrome.
No. of patients Percentage p-Value
27 25.00 0.01
56 51.90
25 23.10
65.00 (54.50–73.75)
58 53.70 0.53
50 46.30
40 37.00 0.049
41 38.00
27 25.00
3 2.80 0.968
34 31.70
66 61.10
5 4.60
9 8.30 0.144
35 32.40
45 41.70
19 17.60
24.12 (21.25–26.87)
20 34.44 0.971
38 65.56
88.00 (93.50–98.00)
4 6.00 0.817
54 94.00
0.97 (0.93–1.02)
5 10.00 0.748
45 90.00
88.00 (84.00–92.00)
1 2.00 0.926
49 98.00
0.94 (0.91–0.98)
 (6 patients didn’t complete follow up)
Total number  of patients with ACS 
                    (n = 114) 
Total nu mber included in the 
final analysis (n= 108) 
   STEMI 
   (n=44) 
NSTEMI 
    (n=41)
Unstable angina 
        (n=23) 
Fig. 1 – Patients with ACS enrolled in the study.
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years, majority of the patients (56/108, 52%) were 55–75 years of
age while almost equal proportions were less than 75 years of
age. The sex distribution showed a nearly equal male 58 (54%)
and female 50 (46%) ratio.
The patients' socioeconomic status was calculated using
the Kuppuswamy's modiﬁcation for Nepal.8 There were 66
(61%) patients in the upper lower strata whereas 34 (32%)
belonged to middle group, 5 (5%) were in lower group, and 3
(3%) were in the upper group. The median body mass index
(BMI) was 24.12 kg/m2. The waist to hip ratio for the males was
0.97 and that of the females was 0.94.
Out of the presenting complaints, the most common was
chest pain 71 (66%) and then shortness of breath 60 (56%),
epigastric discomfort 38 (35%) followed by palpitations 32
(30%), whereas 22 (20%) patients had syncope. Other symp-
toms include cough (1%), fever (6%), headache (1%), altered
sensorium (1%), loose stools (3%), nausea/vomiting (10%), and
diaphoresis (30%).
It was observed that 74 (69%) patients had hypertension
and 32 (30%) patients had a history of diabetes, 24 (22%) had
CAD in past, and 11 (10%) patients had renal disease
previously. Fifty-seven (53%) patients were smokers, and
among the smokers, 50 (46%) had more than 10 pack years
of smoking. Regarding physical activity, 52 (48%) had a
sedentary lifestyle.
On examination, the median pulse rate was 84/min (68–92).
The median systolic blood pressure was 140 mmHg and the
diastolic being 90 mmHg (Table 2).
The median leukocyte count was 12,300 cells/mm3. Other
baseline investigations were in the normal range. The lipid
proﬁle analysis of the patients showed a normal range. The
median triglyceride was 132.50 mg/dl (98–177), cholesterol
was 138.50 mg/dl (107.50–178.00), HDL was 38.00 mg/dl (37–
40), and the median calculated LDL was 67.20 mg/dl (45.05–
110.90). It was seen that 5 (5%) of the patients had
hypoglycemia on presentation, whereas 81 (75%) had a
random blood sugar level above 200 mg/dl. These patientswere then subjected to blood sugar fasting and/or HbA1c
estimation to conﬁrm the diagnosis of diabetes mellitus if it
was not established (Table 3).
The CK NAC showed a median of 301.50 mg/dl (106–811).
Among the group, it was seen that 86 (80%) patients had a
raised CK NAC levels. The median CK MB level was 40 mg/dl
(20–90.25) and 76 (70%) of the patients had raised CK MB levels.
The qualitative troponin I estimation showed positive results
only in 44 (41%) of the patients. The median eGFR on admission
was 45.59 ml/min/1.73 m2. The hs-CRP levels on admission
showed a median value of 24.50 mg/dl (8.25–74.75). The urine
routine examination done using multistix on admission
showed albuminuria of range trace/1+ (30 mg/dl) in 32 (30%)
patients and 2+/3+ (100/300 mg/dl) in 15 (14%) patients
(Table 4).
On follow-up at the 6 weeks and 6 months, the median
eGFRs were 55.27 ml/min/1.73 m2 (40.11–66.18) and 59.02 ml/
min/1.73 m2 (45.35–68.58) and the median hs-CRP values were
8 mg/dl (4–12.50) and 5 mg/dl (3–11), respectively. Among the
patients with ACS, 23 (21%) were diagnosed to have UA, 41
(38%) had NSTEMI and 44 (41%) had STEMI.
The most dominant wall involvement was anterior wall in
68 (63%) patients, while 23 (21%) had inferior wall. Whereas 15
(14%) had lateral wall and 2 (2%) had septal wall involvement.
In the patients with ACS, 56 (52%) had a Killip class of I.
This study showed that 10.28 (26%) of the patients had
arrhythmias. The most common arrhythmia was atrial
ﬁbrillation followed by ventricular arrhythmias and then the
bundle branch blocks whereas 24 (22%) of the total patients
had cardiogenic shock during the index event, 2 (2%) patients
had ischemic events, and 9 (8%) had uncontrolled hyperten-
sion. The other complications included coagulopathy (1%),
hemoptysis (1%), and intracranial hematoma (1%).
The mean duration of hospital stay was 6 days. There were
12 patients who died during the hospital stay whose cause of
death is known and for 2 patients the cause of death is
unknown, and 16 died during the follow-up period. The in-
hospital mortality rate was 11% whereas overall mortality at 6
months follow-up was 28% including all the patients from the
index event until ﬁnal outcome at 6 months.
Cardiogenic shock was seen in six (6%), sudden cardiac
death in four (4%), and ventricular tachycardia in two (2%) of
the patients who died during the index event.
The bivariate analysis was performed and the data were
compared in two groups. G1 represented improved outcome
whereas G2 included mortality at the end of 6 months follow-
up.
The distribution of age was comparable in both the groups.
Age >75 years showed statistical signiﬁcance with all-cause
mortality ( p = 0.011). There was no signiﬁcant association with
mortality in sex, occupation of the patient, and Kuppuswamy's
scale for socioeconomic status or BMI. Those who were not
formally educated had increased all-cause death ( p = 0.049).
The abdominal circumference and waist to hip ratio were not
statistically signiﬁcant.
The systolic blood pressure <90 mmHg was associated with
increased chances of mortality but was not statistically
signiﬁcant ( p = 0.058).
There were no signiﬁcant differences in the mean total
leukocyte count and hemoglobin level in between mortality
Table 2 – Laboratory findings of patients with acute coronary syndrome on admission.
Investigations Categories No. of patients Percentage p-Value
Total leukocyte count/mm3 <4000 1 0.90 0.088
4000–11,000 45 41.70
>11,000 62 57.40
Median TLC (IQR) 12,300.00 (9050.00–16,425.00)
Differential count neutrophil % <50 4 3.70 0.244
50–70 41 38.00
>70 63 58.30
Median DLC neutrophil count (IQR) 73.50 (64.25–82.00)
Differential count lymphocyte % <20 34 31.48 0.303
20–40 60 55.55
>40 14 12.97
Median DLC lymphocyte count (IQR) 26.00 (17.00–34.75)
Hemoglobin (gm/dl) <12 47 43.51 0.146
12–13 9 8.33
>13 52 48.16
Median hemoglobin (IQR) 12.45 (10.65–14.770)
Urea (mg/dl) <10 0 0.00 0.007
10–40 74 68.50
>40 34 31.50
Median urea (IQR) 29.00 (23.00–51.50)
Sodium (mmol/l) <135 9 8.30 0.028
135–145 76 70.40
>145 23 21.30
Median serum sodium (IQR) 141.00 (138.00–145.00)
Triglyceride (mg/dl) <80 11 10.19 0.160
80–200 83 76.88
>200 14 12.93
Median triglyceride (IQR) 132.50 (98.00–177.00)
Total cholesterol (mg/dl) <200 96 88.88 0.810
200–239 11 10.19
>240 1 0.93
Median total cholesterol (IQR) 138.50 (107.50–178.00)
HDL cholesterol (mg/dl) <40 66 61.11 0.994
40–60 42 38.89
>60 0 0.00
Median HDL cholesterol (IQR) 38.00 (37.00–40.00)
LDL cholesterol (mg/dl) <70 59 54.63 0.850
70–<100 19 17.60
100–129 19 17.60
130–159 9 8.34
>160 2 1.83
Median LDL cholesterol (IQR) 67.20 (45.05–110.90)
Blood sugar level random (mg/dl) <60 5 4.62 0.058
60–200 22 20.38
>200 81 75.00
Median blood sugar level (IQR) 119.00 (90.00–178.00)
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 29.36 in the improved group but it was signiﬁcantly higher
(50.03  30.92) in the death group ( p = 0.007). Similarly, the
serum sodium level >145 mmol/l was signiﬁcant for death
( p = 0.028). Although blood sugar levels >200 mg/dl and
<60 mg/dl were associated with overall mortality, it was
statistically not signiﬁcant ( p = 0.058). The mean eGFR in the
mortality group was 36.68  19.74 mg/dl in the death group
( p = 0.012). The hs-CRP level at admission was highly signiﬁ-
cant ( p = 0.001) with a mean value of 54.37 mg/dl in themortality. Similarly, albuminuria of 30 mg/dl and above was
signiﬁcant for mortality ( p = 0.002).
The type of ACS was not statistically signiﬁcant. The Killip
class IV was associated with increased mortality ( p = 0.007).
In-hospital mortality during the index event was signiﬁ-
cant ( p = <0.001). The mean duration of stay in the
death group was 6.89  7.53 days. In the causes of mortality,
ventricular tachycardia was the most signiﬁcant ( p = <0.001)
followed by sudden cardiac death and cardiogenic shock
(Tables 5 and 6).
Table 3 – Cardiac markers of patients with acute coronary syndrome on admission.
Cardiac markers Categories No. of patients Percentage p-Value
CK NAC (mg/dl) <90 22 20.30 0.950
≥90 86 79.70
Median CK NAC (IQR) 301.50 (106.00–811.50)
CK MB (mg/dl) <25 32 29.70 0.612
>25 76 70.30
Median CK MB (IQR) 40.00 (20.00–90.25)
Cardiac troponin I Negative 64 59.30 0.593
Positive 44 40.70
eGFR at admission (ml/min/1.73 m2) <30 34 31.50 0.012
30–59 53 49.10
>60 21 19.40
Median eGFR at admission (IQR) 45.59 (26.11–57.28)
Highly sensitive CRP at admission (mg/dl) <2 0 0.00 0.001
2–5 21 19.40
>5 87 80.60
Median hs-CRP at admission (IQR) 24.50 (8.25–74.75)
Urine albumin Nil 61 56.50 0.002
Trace/1+ 32 29.60
2+/3+ 15 13.90
CK, creatine kinase; hs-CRP, high sensitivity C-reactive protein; eGFR, estimated glomerular ﬁltration rate.
Table 4 – Laboratory findings of patients with acute coronary syndrome at 6 weeks and 6 months.
Investigations Categories 6 weeks p-Value 6 months p-Value
No. of patients Percentage No. of patients Percentage
eGFR (ml/min/1.73 m2) <30 11 12.80 0.298 7 8.97 0.384
30–59 44 51.16 34 43.60
>60 31 36.04 37 47.43
Median eGFR (IQR) 55.27 (40.11–66.18) 59.02 (45.35–68.58)
Highly sensitive CRP (mg/dl) <2 0 0.00 0.642 0 0.00
2–5 35 32.40 41 38.00
>5 73 67.60 67 62.00
Median hs-CRP (IQR) 8.0 (4.00–12.50) 5.00 (3.00–11.00)
hs-CRP, high sensitivity C-reactive protein; eGFR, estimated glomerular ﬁltration rate.
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6 months period (Table 7).
For the multivariate analysis, the variables at a signiﬁcance
level of p = ≤0.05 in the bivariate analysis were taken. TheTable 5 – Outcome of patients with acute coronary syndrome a
Outcome Categories 
Death at 6 weeks Yes 
No 
Acute coronary syndrome at 6 weeks Yes 
No 
New York Heart Association at 6 weeks in class I 
II 
III 
IV 
PCI/CABG at 6 weeks Yes 
No multivariate analysis showed that age, hs-CRP, albuminuria,
and cardiogenic shock were strongest predictors of mortality
when used in relation to each other. In the study, the cause of
death was not known in two patients who had died during thet 6 weeks.
No. of patients Percentage p-Value
9 8.30 <0.001
85 78.70
3 2.80 0.230
82 75.90
31 28.70 0.097
42 38.90
12 11.10
0 0.00
7 6.50 0.508
79 73.10
Table 6 – Outcome of patients with acute coronary syndrome at 6 months.
Outcome Categories No. of patients Percentage p-Value
Death at 6 months Yes 7 6.50 <0.001
No 78 72.20
New York Heart Association at 6 months in class I 40 37.00 0.740
II 34 31.50
III 4 3.70
IV 0 0.00
PCI/CABG at 6 months Yes 4 3.70 0.780
No 74 68.50
Final status of patients at 6 months Improved 78 72.20 <0.001
Death 30 27.80
Table 7 – Outcome in patients with acute coronary syndrome by mortality or no mortality.
Outcome Categories Improved Mortality p-Value
Death at 6 weeks Yes 0 9 <0.001
No 78 7
Death at 6 months Yes 0 7 <0.001
No 78 0
Outcome ﬁnal Improved 78 0 <0.001
Death 0 30
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facility was available in our setup. The samples of the patients
were collected in the emergency, but as the cause of death was
not known, they were not included in the in-hospital mortality
data analysis. As their discharge status was considered death,
they were included in the ﬁnal analysis. The ﬁnal outcome of
the study was all-cause mortality.
5. Discussion
In this series, 114 consecutive patients were studied. The age
of the patients ranged from age 27 to 92 years with the median
age of 65 years, which is similar with the studies done in the
same setting.9,10 The mean age at diagnosis was 64 years in a
study done at western part of Nepal.11,12 Thus, it was seen that
the prevalence is higher in older age group and with higher
mortality rate. It was statistically signiﬁcant with age >75
years. Age is a powerful predictor of adverse events after ACS.
In a study on ACS in Nepal, it is stated that death claims mostly
the elderly population; in US, 83% of IHD deaths were in
patients of more than 65 years of age as per the GRACE
registry.12–14 In the study, 27 patients were less than 55 years of
age, which is also similar to the study done previously in the
same setting.10 There is an increasing trend of young people
having ACS. The male to female ratio is 1.16:1 whereas in
previous study, it was 1.6:1, but in other studies from Nepal, it
was 1.14:1,9 which varied with sample size and study settings.
The median leukocyte count was 12,300 cells/mm3. The
leukocytosis was in response to the inﬂammatory nature of
ACS. In a study, it was seen that there was an epidemiological
association indicating a worse angiographic appearance of theculprit lesion with higher white blood count at presentation
with ACS.15 The level of blood urea above 40 mg/dl was
signiﬁcantly associated with all-cause mortality during the
index event and also during the 6 months period. There was a
statistical signiﬁcance with low eGFR (median eGFR 45.59 ml/
min/1.73 m2) levels during the admission. It was also associ-
ated with high serum sodium levels. It is arguable on the basis
of these observations that the patients are mainly dehydrated
(high urea, low eGFR, and high sodium levels) in the mortality
group. These all were statistically signiﬁcant at the ﬁnal
outcome. The most important was the creatinine levels at
admission. The eGFR in VALIANT study, where the four-
component MDRD equation was used, found that the
distribution of estimated GFR was wide and normally shaped,
with a mean (SD) value of 70  21 ml/min/1.73 m2 of body-
surface area, the probable reason of this difference being
primarily that we used median in our analysis and secondly
ethnicity being one of the variables.16 A more recent analysis
from the GUSTO (Global Utilization of Strategies To Open
occluded arteries) IV study found that creatinine clearance and
troponin elevation provided the greatest relative contribution
to risk (1-year mortality or 30-day mortality/MI) beyond
traditional risk factors.17
There have been different studies on the risk stratiﬁcation
of CK MB, but in one study done by Alexander et al., it showed a
statistical difference in 30-day mortality even if there was
increase in the level of CK MB levels 1–2 times the upper
normal. In this study, the median CK MB level was 40 mg/dl,
but there was no statistical signiﬁcance for risk stratiﬁcation.
The reasons may be due to smaller sample size when
compared with the other study where it is very large.18
Secondly, the patients presented with a median duration of
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normal level within 72 h, this delayed presentation gives us a
different picture. It was seen that there is a low triglyceride
levels (<200 mg/dl) in the Caucasian patients with ACS if taken
within 24 h of admission. The study showed low triglyceride
level to be an independent predictor of mortality at 3 years
from the index event. In this study, the mean triglyceride
levels was 161.53  76.55 mg/dl, which is in lower range with
the given reference limit. This is also similar to the studies
done on ACS in the same setting.19
In this study, the hs-CRP levels of >5 mg/dl were highly
signiﬁcant for predicting mortality during hospital stay and at
6 weeks. In the GRACE registry, 12% of patients with STEMI,
13% with NSTEMI, and 8% with UA were expected to die in 6
months within onset of symptoms.20 There have been a
number of studies done which found the prognostic signiﬁ-
cance of hs-CRP. Most of the studies were done in stable CAD.
The JUPITER trial, which was restricted to participants with
CRP levels >2 mg/l, found that treating the patients with
rosuvastatin decreased the hs-CRP and LDL levels and the
cardiovascular outcomes.21
In this study, microalbuminuria was not taken as a variable,
as it was studied earlier but urine sample was sent for routine
analysis, which was done from multistix/uristix kit on every
patient with ACS. It was found that albuminuria was a
predictor of mortality. The more the level of albumin on
admission, there was increased mortality. Acuna et al.22 found
microalbuminuria to be an independent risk factor of heart
failure (OR = 1.75; 95% CI = 1.02–3.01; p = 0.04) and of mortality
(OR = 2.6; 95% CI = 1.05–6.41).
In a study done in western Nepal, involvement of ACS was
most common in anterior wall and inferior wall than any
others wall.11 In this study, it was found there was a very
similar involvement. This was also similar to the study on ACS
at BPKIHS done previously. In a study, it was seen that
arrhythmias were in 27%, similar to the ﬁndings of this study,
where 26% of patients had arrhythmias and it was found
statistically signiﬁcant for predicting mortality. Cardiogenic
shock complicating STEMI resulted in high mortality.11 It was
observed that there was 11% in-hospital mortality in this
study. From the study, if the total in-hospital mortality
irrespective of the cause of death was taken, then it was
found to be 13% (2 cases were excluded as the cause of death
was not known). The high in-hospital mortality (14%) was
observed in other study.10 This can be ascribed to markedly
delayed presentation, lack of resources for the best possible
available care, and major logistic difﬁculties to organize timely
PCI. During the study period, there were no facilities for PCI at
this setting. Similarly, in other study from Nepal, the in-
hospital mortality was 12%.11 Outcomes at 6 weeks period
showed a signiﬁcant mortality. The duration of hospital course
was almost similar when compared with other contemporary
international surveys like GRACE registry. At 6 months, the
overall mortality was 28%, which is highly signiﬁcant. No other
study was done in this setting to compare results at 6 months
duration.
We also searched to look for other studies in Nepal which
did a follow-up of the patients. We found a registry of patients
in western Nepal, but data for 6 months period were lacking in
that study.Logistic regression analysis of the variables studied was
done. Only those variables, which were signiﬁcant at p ≤ 0.05 in
the bivariate analysis, were taken for multivariate analysis to
increase the statistical signiﬁcance. It was found that age >55
years; albuminuria and cardiogenic shock at the index event
remained as a strong predictor of all-cause mortality in
patients with ACS in relation to each other. Similarly, hs-CRP
levels >5 mg/dl and CK levels at the index event are also a
strong predictor of mortality.
6. Summary and conclusion
The levels of serum hs-CRP, serum blood urea, serum
creatinine, and albuminuria (done using a simple uristix/
multistix test) at admission are statistically signiﬁcant
independent predictors of death in patients of ACS at the
index event at 6 weeks and at 6 months.
When the signiﬁcant biomarkers and the signiﬁcant
established risk factors were studied in relation to each other,
hs-CRP levels were signiﬁcant along with age in predicting
outcomes. Fluid balance is a very important aspect and we
need to do a bigger study with larger sample size to generalize
this observation.
7. Limitations
In our setting, we did not have facilities for estimation of
quantitative levels of troponin and novel biomarkers like
NTproBNP, which are more speciﬁc and better tools for
predicting outcomes in patients with ACS. During the study,
there were no facilities for cardiac catheterization at our
setting.
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